Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RESTORING SENSITIVIT

Financiado

Cerrado

Rendering environmental pathogens sensitive to antibiotics prior to infection

Antibiotic resistance of pathogens is an accelerating problem and there is an urgent need for new antimicrobial agents. Pharmaceutical companies face numerous obstacles in developing new antibiotics, and therefore a method that w... ver más

31/08/2014

TAU

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-08-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

TAU

0.00€ | Lider

THE FOUNDATION FOR MEDICAL R...

TASMC

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PHAGE Structure and dynamics of PHage Attachment and Genome Ejecti... 150K€ Cerrado

ENABLE European Gram Negative Antibacterial Engine 101M€ Cerrado

BACtheWINNER Bacteriocins from interbacterial warfare as antibiotic alter... 3M€ Cerrado

NEXTER Next generation eco friendly microbiome preserving and redu... 150K€ Cerrado

PID2020-117708GB-I00 CARACTERIZACION DE LOS MECANISMOS DE RESISTENCIA ADQUIRIDOS... 121K€ Cerrado

PID2021-124464NB-I00 LA RESPUESTA BACTERIANA A FAGOS MAS ALLA DE LOS SISTEMAS CRI... 121K€ Cerrado

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Antibiotic resistance of pathogens is an accelerating problem and there is an urgent need for new antimicrobial agents. Pharmaceutical companies face numerous obstacles in developing new antibiotics, and therefore a method that will re-sensitize pathogens to well-established antibiotics harbors key advantages. We propose a system that restores antibiotic efficiency by reversing resistance of pathogens. The system utilizes bacteriophages, which possess engineering capabilities and are excellent, protected delivery vehicles. Unlike bacteriophage therapy, the proposed system does not rely on the ability of the phages to kill pathogens, but instead, to deliver genetic constructs to nosocomial pathogens rendering them sensitive to antibiotics prior to host infection. Pathogen-specific phages will be engineered with genes conferring sensitivity to an antibiotic of choice in a dominant fashion and small RNAs that target preferred resistance genes. Including a resistance marker to tellurite, a compound toxic to bacteria, will be used to generate a selective pressure, enriching for pathogens that harbor the phages. Genetic systems and molecular biology techniques will be used to maintain the phage in the pathogens and to ensure their transfer only as a complete unit, thus enhancing efficiency and providing safety measures. The proposed system may be used to render the pathogens susceptible to multiple antibiotics in a single construct. This will dramatically reduces evolvement of simultaneous resistance against multiple antibiotics. Extended treatment with the tellurite and the engineered phage will significantly enrich for antibiotic-treatable pathogens in nosocomial infections and in vast contrast to antibiotics and phage therapy, will change the nosocomial infections more susceptible to the proposed treatment. Moreover, the approach evades phage usage in the patient thus overcoming toxicity issues and neutralization of the phage by the spleen and the immune system.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores